Nektar Therapeutics Q3 EPS $(1.63) Beats $(2.08) Estimate, Sales $9.386M Miss $10.274M Estimate. Cash and Investments $952.9M
Benzinga Newsdesk 17 hours ago
NewsEarningsEarnings BeatsEarnings Misses
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.63) per share which beat the analyst consensus estimate of $(2.08) by 21.63 percent. This is a 12.83 percent increase over losses of $(1.87) per share
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.63) per share which beat the analyst consensus estimate of $(2.08) by 21.63 percent. This is a 12.83 percent increase over losses of $(1.87) per share from the same period last year. The company reported quarterly sales of $9.386 million which missed the analyst consensus estimate of $10.274 million by 8.64 percent. This is a 20.39 percent decrease over sales of $11.790 million the same period last year.